score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Clinical evidence	Copy Number	PAK1	Amplification				0.0	0.0																Putatively Actionable	0.0	PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				PAK1 Amplification		Osteosarcoma-WABS378	WABS378_T	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.229						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (23%)		Osteosarcoma-WABS378		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.4103	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	47.0	0.5319	1.0	TP53 p.V173M (Missense)		Osteosarcoma-WABS378	Osteosarcoma-WABS378-Tumor-SM-2RCBS	Osteosarcoma-WABS378-Normal-SM-2RCD8
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						Osteosarcoma-WABS378		
Investigate Actionability	FDA-Approved			Rearrangement	ABL1	Fusion	ABL1--TTF1			0.0	0.0		Investigate Actionability	Bosutinib	targets BCR-ABL	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.	Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf													0				ABL1--TTF1 Fusion	1.0	Osteosarcoma-WABS378		
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.R582H	0.06	50.0	1.6e-05	0.0																					0	0.0	0.0	0.0	NTRK2 p.R582H (Missense)		Osteosarcoma-WABS378	Osteosarcoma-WABS378-Tumor-SM-2RCBS	Osteosarcoma-WABS378-Normal-SM-2RCD8
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.254																									0				COSMIC Signature (version 2) 6 (25%)		Osteosarcoma-WABS378		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.204																									0				COSMIC Signature (version 2) 15 (20%)		Osteosarcoma-WABS378		
